trending Market Intelligence /marketintelligence/en/news-insights/trending/U_O8s-_aVPOnHbTa2kFVBg2 content esgSubNav
In This List

Summit Therapeutics names COO

Blog

Insight Weekly: Loan-to-deposit ratio rises; inventory turnovers ebb; miners add female leaders

Blog

Debt Ceiling Debate: IR Teams Should Prepare for Potential Market Downturns

Blog

Insight Weekly: Sustainable bonds face hurdles; bad loans among landlords; AI investments up

Blog

Insight Weekly: Bank oversight steps up; auto insurers’ dismal year; VC investment slumps


Summit Therapeutics names COO

Summit Therapeutics PLC appointed David Roblin COO and president of research and development.

Roblin will lead research and development and commercial functions to support the development of the company's Duchenne muscular dystrophy and C. difficile infection programs. Roblin, who has been acting as a research and development adviser to Summit since 2014, will assume his new role on an interim basis in April, and become permanent in June.

He was most recently COO and director of scientific translation at the Francis Crick Institute, a London-based biomedical institute.